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A B S T R A C T
Imatinib inhibits the activity of several tyrosine kinases, including BCR-ABL, KIT and platelet-derived growth
factor receptor (PDGFR). Dysregulation of KIT is found in mast cell tumours (MCTs) and KIT is mutated
in approximately 30% and 70% of canine and feline MCTs, respectively. KIT mutations have also been re-
ported in canine and feline gastrointestinal stromal tumours (GISTs), canine acute myeloid leukaemia
and canine melanoma. In addition, BCR-ABL and PDGFR mutations have been found in canine leukaemia
and haemangiosarcoma, respectively. Imatinib has anti-tumour activity with tolerable toxicity towards
a certain subset of MCTs in dogs and cats. Favourable clinical responses are likely to be associated with
the presence of KITmutation. Anti-tumour activity of imatinib has also been demonstrated in canine GISTs
with a KITmutation and in feline hypereosinophilic syndrome; however, to date only one of each of these
cases has been reported. In conclusion, analysis of KIT mutations appears to provide valuable data for
individual treatment with imatinib in dogs and cats.
© 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Since the discovery of KIT dysregulation due to mutations in
canine mast cell tumours (MCTs) (London et al., 1999; Ma et al.,
1999), veterinary oncology research with a focus on targeted therapy
using tyrosine kinase inhibitors (TKIs) has dramatically increased.
Two TKIs (toceranib and masitinib) have entered the clinic (Hahn
et al., 2008; London et al., 2009) and are currently changing the ther-
apeutic approach for malignancies in dogs and cats.
The small-molecule TKI, imatinib (Novartis; also known as
Gleevec or Glivec), is a prototype of target-oriented drugs in humans.
It has sparked a revolution in cancer therapy by dramatically im-
proving treatment for chronic myeloid leukaemia (CML) in humans
(Druker et al., 2001). Imatinib targets BCR-ABL, KIT, platelet-
derived growth factor receptor (PDGFR), colony stimulating factor
1 receptor, ABL1, ABL2, discoidin domain receptor 1/2 and
lymphocyte-speciﬁc protein tyrosine kinase (Deininger et al., 2005;
Dewar et al., 2005; Manley et al., 2010).
Some tumours in dogs and cats possess mutations in these ty-
rosine kinases; therefore, imatinib is one of a number of potential
target-oriented therapeutic approaches for canine and feline neo-
plasms. The aim of this article is to review the current knowledge
regarding the dysregulation of kinases and the therapeutic effects
of imatinib in canine and feline neoplasms, particularly in MCTs.
KIT and other potential targets for imatinib in canine and
feline tumours
Among the potential targets for imatinib, KIT, which is ex-
pressed in MCTs, has been the most extensively studied in dogs and
cats. To date, there is only limited information available regarding
other potential targets in canine and feline tumours.
KIT mutations in canine mast cell tumours
The reported location and frequency of KIT mutations in canine
MCTs are summarised in Table 1. KIT mutations have been ob-
served in approximately 30% of canine MCTs (Letard et al., 2008;
Takeuchi et al., 2013). KIT mutations are most frequently found in
exon 11 (~14–21%) and primarily consist of internal tandem du-
plication (ITD) mutations (9–17%) in randomly selected MCT cases
(Zemke et al., 2002;Webster et al., 2006; Letard et al., 2008; Takeuchi
et al., 2013). Other than exon 11 mutations, mutations have been
found in exons 2, 6, 7, 8, 9, 15 and 17 (Letard et al., 2008; Takeuchi
et al., 2013). Compared with mutations in exon 11, mutations in
exons 8 and 9 are less frequent, although a signiﬁcant number of
mutations have been identiﬁed (Letard et al., 2008; Takeuchi et al.,
2013). Mutations in other exons are generally infrequent (<3%).
A high incidence of exon 11 ITD mutations has been reported
in higher gradeMCTs classiﬁed according to Patnaik grades (Downing
et al., 2002; Zemke et al., 2002; Webster et al., 2006). Although no
signiﬁcant differences in the frequency of the exon 11 ITD muta-
tion were observed in MCTs across Patnaik grades, the frequency
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of this mutation in Kiupel high grade MCTs was signiﬁcantly higher
than that in low grade tumours (Takeuchi et al., 2013). Moreover,
the presence of exon 11 ITD mutation is associated with an in-
creased incidence of recurrent disease, metastasis, death or shorter
progression-free survival (Downing et al., 2002;Webster et al., 2006;
Takeuchi et al., 2013). All these reports suggest an association
between clinical aggressiveness and the presence of ITD muta-
tions, suggesting that imatinibmay have therapeutic utility for canine
MCTs with aggressive behaviour.
Although mutated KIT is an important target for imatinib in
canine MCTs, genetic heterogeneity within the same tumour and/
or between different tumours from the same patient (primary
tumour vs. metastasis) could exist. In humans, the presence of
intratumoral genetic heterogeneity inﬂuences therapeutic re-
sponse and contributes to resistance against kinase inhibitors (Bedard
et al., 2013). However, in dogs, Marconato et al. (2014) observed
no difference in the mutation status of KIT between primary canine
MCTs and their corresponding metastases. In contrast, Amagai et al.
(2013) reported that two cases of canine MCT had an ITD muta-
tion in the primary lesion but not in the secondary lesion. The latter
ﬁnding implies the presence of heterogeneity in KITmutational status
among different geographical regions of MCTs, similar to that re-
ported for various human tumours (Bedard et al., 2013). Genetic
heterogeneity could therefore be an issue when using imatinib
therapy for canine MCTs.
KIT mutation in feline mast cell tumours
The mutational status of KIT in feline MCT is summarised in
Table 2. Isotani et al. (2010) found that 67.7% of feline MCTs had a
mutation in KIT. The majority of the mutations were identiﬁed in
exon 8, where theymostly consisted of an ITDmutation, and in exon
9. Sabattini et al. (2013) reported that 62.5% of cats with MCT had
a mutation in at least one of their multiple nodules and that the
majority of these mutations were found in exons 8 and 9. Al-
though the most frequent mutation was reported to be in exon 8
(45.2% of cases) in the study of Isotani et al. (2010), it was re-
ported to be in exon 9 (50.0% of cases) in the study of Sabattini et al.
(2013). The reason for this difference is unclear, but could reﬂect a
difference in the tumour population (e.g. visceral vs. cutaneous). Al-
though Dank et al. (2002) investigated KIT mutation in exons 11,
12 and 17 in 10 cats with MCT, no mutation was identiﬁed. Thus,
KITmutations appear to bemore frequent in felineMCTs than canine
MCTs, and the ‘hotspot’ of mutation differs from that of canineMCTs.
Furthermore, in contrast to canine MCTs, no signiﬁcant relation-
ship between KIT mutation status and tumour behaviour was
observed for feline MCT (Sabattini et al., 2013).
Sabattini et al. (2013) demonstrated that multiple nodules from
the same cat had different KIT mutational status; one cat had two
tumour nodules that each showed a different mutation, while ﬁve
cats had tumour nodules in the same subject with or without KIT
mutations. As speculated for canine MCTs, some feline MCTs may
have genetic heterogeneity in the same animal.
KIT mutations in canine and feline gastrointestinal stromal tumours
KIT mutations have been detected in canine and feline gastro-
intestinal stromal tumours (GISTs). In dogs, Frost et al. (2003)
reported that 2/4 cases had a deletion/insertion or a substitution
mutation (KIT exon 11 was examined) and Gregory-Bryson et al.
(2010) reported that 6/17 cases had deletion mutations in KIT
exon 11 (KIT exons 8, 9, 11, 13 and 17, and PDGFRA exons 12, 14
and 18, were examined). A deletion mutation in KIT exon 11 was
also identiﬁed in a case of canine GIST (Kobayashi et al., 2013)
and a deletion mutation in KIT exon 11 has been reported in a
case of feline GIST (Morini et al., 2011). There was an overlap
between canine and feline GIST mutations with one of the hotspots
of driver mutations in human GIST (Corless et al., 2011). A substi-
tution mutation reported by Frost et al. (2003) in canine GIST has
also been reported in some human GISTs (Lasota et al., 1999).
Although the number of cases examined is still small, these
studies indicate that a certain subset of canine and possibly feline
GISTs may share similar molecular features with human GISTs
and that mutant KIT could be a potential therapeutic target of
imatinib in these tumours.
KIT mutations in canine leukaemia and lymphoma
Usher et al. (2009) examined the mutation status of KIT exons
8, 10, 11 and 17 in canine acute leukaemias (myeloid, lymphoid and
undifferentiated). In this study, 3/21 cases of acute myeloid leu-
kaemia had KIT mutations (one mutation in each of exon 11 and
17, one mutation in exon 17 or two mutations in exon 17). In con-
trast, no KIT mutation was found in cases of acute lymphoid
leukaemia (n = 14) or acute undifferentiated leukaemia (n = 1).
Giantin et al. (2013a) also investigated the presence of mutations
Table 1
Reported frequency of KIT mutation in randomly selected canine mast cell tumours.
Number of cases Region of KIT examined Frequency of mutation (%) Reference
Exon 8 Exon 9 Exon 11 (ITD) Other exons Total
47 Entire KIT 6.4 0 21.3 (17.0) <3 34.0 Takeuchi et al. (2013)
191 Exons 8–13 and 17–19 4.7 4.2 16.8 (13.1) <3 26.2a Letard et al. (2008)
88 Exon 11 NA NA 13.6 (9.1) NA NA Zemke et al. (2002)
60 Exon 11 NA NA NA (13.3) NA NA Webster et al. (2006)
NA, not available; ITD, internal tandem duplication mutation.
a Value indicates the total frequency of mutations in exons 8–13 and 17–19.
Table 2
Reported frequency of KIT mutation in randomly selected feline mast cell tumours.
Number of cases Region of KIT examined Frequency of mutation (%) Reference
Exon 6 Exon 8 (ITD) Exon 9 Exon 11 Other exons Total
62 Entire KIT or exons 8, 9, 11, 13, and 17 5.9a 45.2 (40.3) 24.2 1.6 0 67.7 Isotani et al. (2010)
24 Exons 8, 9, and 11 NA 16.7b (8.3b) 50.0b 8.3b NA 62.5b Sabattini et al. (2013)
NA, not available; ITD, internal tandem duplication mutation.
a Mutation in exon 6 was examined in 17 cats and one cat had a mutation.
b The frequency of mutation was recalculated from the original report as the percentage of cats that had a mutation in at least one of their multiple nodules.
181M. Bonkobara/The Veterinary Journal 205 (2015) 180–188
in KIT exons 8–11 and exon 17 in 11 cases of acute leukaemias
(lymphoid, n = 4; undifferentiated leukaemia, n = 7) and in 12 cases
of chronic lymphocytic leukaemias, but found no mutations.
All three cases of acute myeloid leukaemia with KIT mutations
had a mutation in the kinase domain that altered Asp815 (corre-
sponding to human Asp816) to Val (n = 2) or Asn (n = 1) (Usher et al.,
2009). KIT with Asp816 mutations, especially the Asp816Val mu-
tation, has been shown to be highly resistant to imatinib in humans
because thismutation causes a conformational change in KIT towards
the active form (Ma et al., 2002; Foster et al., 2004). Thus, canine
acute myeloid leukaemias carrying KIT Asp815 mutations may not
respond to imatinib.
KIT mutations in lymphoma were investigated by Giantin et al.
(2013b), who examined mutations in KIT exons 8–11 and 17 in B
cell lymphomas (n = 25) and T cell lymphomas (n = 21), but no mu-
tation was identiﬁed.
KIT mutations in canine melanomas
Chu et al. (2013) examined the mutational status of KIT exon 11
in canine malignant melanomas that had developed at different an-
atomical sites (n = 49) and found a missense mutation in 1/33 case
of oral melanoma. Murakami et al. (2011) also examined the mu-
tational status of KIT exon 11 in canine oral melanoma (n = 17), but
no mutation was identiﬁed. In humans, Beadling et al. (2008) dem-
onstrated that 15.6% of mucosal melanomas displayed KITmutations,
which commonly occurred in exon 11, and that imatinib was ef-
fective for patients with mucosal melanoma that carried a KIT
mutation (Hodi et al., 2013). Thus, in contrast to humans, KIT mu-
tations seem to be uncommon in canine mucosal melanomas.
Although KIT mutations other than those in KIT exon 11 need to be
examined, canine mucosal melanomasmay not respond to imatinib,
since imatinib did not have a growth inhibitory effect on nine canine
malignant melanoma cell lines (Ito et al., 2013).
BCR-ABL in canine leukaemia
Chromosomal translocations between the ABL gene on chromo-
some 9 and the BCR gene on chromosome 26, as well as the presence
of the BCR-ABL fusion protein, have been demonstrated in a canine
CML by ﬂuorescence in situ hybridisation (FISH) and Western blot
analysis, respectively (Breen andModiano, 2008). The BCR-ABL trans-
location has also been detected in three dogs with chronic monocytic
leukaemia (Cruz Cardona et al., 2011; Culver et al., 2013; Pérez et al.,
2013) and in one dog with acute myeloblastic leukaemia (Figueiredo
et al., 2012) by FISH analysis. Although the nucleotide sequence of
DNA fusion junctions for BCR-ABL translocations has not yet been
analysed, these ﬁndings suggest the presence of BCR-ABL in a certain
subset of leukaemia in dogs, which would make imatinib a poten-
tial therapeutic approach for these canine tumours, similar to
humans.
PDGFR mutation in canine haemangiosarcoma
Only one study has demonstrated the presence of PDGFR mu-
tations in canine haemangiosarcomas (Abou Asa et al., 2013). In that
report, 2/27 cases exhibited missense mutations in exon 14 or 17
of PDGFRB. No similar PDGFRB mutations have been reported for
PDGFRB in human neoplasms. Further studies are needed to clarify
the signiﬁcance of these mutations for haemangiosarcoma.
Wild-type tyrosine kinases or tyrosine kinases whose mutation
status is unknown in canine and feline tumours
Aberrant signalling of tyrosine kinases could be caused not only
by speciﬁc mutations, but also by overexpression, which could in-
crease the response of cancer cells to growth factors or induce
receptor dimerisation in the absence of an activating ligand (Zwick
et al., 2002). In dogs and cats, the expression of wild-type
Table 3
Canine and feline tumours expressing KIT or platelet-derived growth factor receptor.
Tumoura Species Detection Reference
KIT Mast cell tumour Dog IHC London et al. (1996), Gil da Costa et al. (2007)
Cat IHC Rodriguez-Cariño et al. (2009), Sabattini and Bettini (2010)
Gastrointestinal stromal tumour Dog IHC Frost et al. (2003), Morini et al. (2004)
Cat IHC Morini et al. (2004), Morini et al. (2011)
Melanoma Dog IHC Murakami et al. (2011), Newman et al. (2012), Chu et al. (2013)
Leukaemia/lymphoma Dog RT-PCR, FACS, IHC Giantin et al. (2013a), Giantin et al. (2013b)
Mammary gland carcinoma Dog RT-PCR, IHC Kubo et al. (1998), Morini et al. (2004), Brunetti et al. (2014)
Cat IHC Morini et al. (2004)
Anal sac adenocarcinoma Dog RT-PCR, IHC Brown et al. (2012), Urie et al. (2012)
Thyroid carcinoma Dog RT-PCR, IHC Urie et al. (2012)
Haemangiosarcoma Dog IHC Sabattini and Bettini (2009)
Seminoma Dog IHC Morini et al. (2004), Hara et al. (2014)
Interstitial cell tumour Dog IHC Morini et al. (2004)
Granulosa cell tumour Dog IHC Morini et al. (2004)
Cat IHC Morini et al. (2004)
Ovarian papillary carcinoma Dog IHC Morini et al. (2004)
Soft tissue ﬁbrosarcomas Cat IHC Smith et al. (2009)
Histiocytic sarcomab Dog RT-PCR, FACS Zavodovskaya et al. (2006)
PDGFRA/B Anal sac adenocarcinoma Dog RT-PCR, IHC Brown et al. (2012), Urie et al. (2012)
Lymphoma Dog RT-PCR, IHC Aricò et al. (2014)
Thyroid carcinoma Dog RT-PCR, IHC Urie et al. (2012)
Haemangiosarcoma Dog IHC Asa et al. (2012)
Osteosarcoma Dog IHC Maniscalco et al. (2013)
Gliomas Dog IHC Higgins et al. (2010)
Vaccine-associated sarcomab Cat WB analysis Katayama et al. (2004)
PDGFRA/B, platelet-derived growth factor receptor-alpha/beta; IHC, immunohistochemistry; RT-PCR, reverse transcription-polymerase chain reaction; FACS, ﬂow cytometry;
WB, Western blot.
a Tumours with low frequency of expression were also included.
b Cell lines.
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tyrosine kinases or of tyrosine kinases whose mutation status is
unknown has been reported for several tumours. For example, KIT
and PDGFR are expressed in various tumours in dogs and cats
(Table 3). This could have important therapeutic implications;
however, it is not clear whether this is suﬃcient for a positive re-
sponse with imatinib. In a recent study of humanmelanomas (Hodi
et al., 2013), a response to imatinib was observed in tumours with
KIT mutations, but not in tumours with ampliﬁcation of wild-type
KIT. In canine haemangiosarcoma cell lines, imatinib inhibited phos-
phorylation of PDGFRB; however, the half maximal inhibitory
concentrations of imatinib for growth of these cells were
50–65 μM (Dickerson et al., 2013), which are substantially higher
than the therapeutic concentrations reported in humans (Cmax of
a standard dose of 400mg is approximately 3 μM; Peng et al., 2004).
Further investigation is needed to understand the relationship
between the expression of KIT, PDGFR and other kinases, and the
therapeutic response to imatinib.
The use of imatinib for dogs and cats in a clinical setting1
Imatinib was originally developed as a therapeutic drug for
human CMLs that targets BCR-ABL (Druker et al., 1996). Subse-
quently, clinical studies indicated a remarkably high therapeutic
response to imatinib by human GISTs, which frequently have KIT
mutations (Debiec-Rychter et al., 2004). Imatinib has also been dem-
onstrated to have anti-tumour activity towards several other tumours
with kinase mutations, such as GISTs with a PDGFRA mutation
(Heinrich et al., 2003), hypereosinophilic syndrome (HES) with a
FIP1L1-PDGFRA fusionmutation (Cools et al., 2003), myelodysplastic/
myeloproliferative neoplasms with PDGFR gene rearrangements
(Verstovsek, 2007), mastocytosis with KITmutations (except for the
KIT D816V mutation) (Pardanani, 2013) and melanoma (mucosal,
acral and chronically sun-damaged) with KITmutations (Hodi et al.,
2013).
Imatinib is a drug developed for humans that has been used off-
label for dogs and cats, similar to most chemotherapeutic drugs in
veterinary medicine. Due to the prohibitive cost of imatinib, it has
been diﬃcult to use imatinib in dogs and cats. However, less ex-
pensive generic versions of imatinib became available after 2013.
Mast cell tumours
In dogs, a total of 28 cases of MCTs treated with imatinib have
been reported; of these, 25 cases were treated with imatinib
(10–12.7mg/kg daily), with examination of KITmutation status (ex-
amination of entire KIT, KIT exons 8, 9 and 11, or KIT exon 11 alone)
(Isotani et al., 2008; Yamada et al., 2011; Kobayashi et al., 2012;
Nakano et al., 2014). In addition to these 25 cases, we have treated
13 cases with imatinib (10–12mg/kg daily) with examination of KIT
mutation status (KIT exons 8, 9, and 11) (unpublished data). Of these
38 cases, 16 cases had a detectable mutation in KIT exon 8, 9 or 11.
All of these 16 cases achieved an objective response (complete or
partial response) to imatinib. Of the 22 cases without a detectable
KIT mutation, only ﬁve cases showed an objective response to
imatinib. Three dogs with aggressive MCTs and an unknown KITmu-
tation status were treated with imatinib (4.4 mg/kg daily) and all
of these dogs achieved a complete response (Marconato et al., 2008).
In cats, 11 cases of MCTs treated with imatinib (10 mg/kg daily)
have been reported and all were examined for KIT mutation (ex-
amination of entire KIT or KIT exons 8, 9, 11, 13 and 17) (Isotani et al.,
2006, 2010). Nine had a mutation in KIT exons 8 or 9 and all, except
one cat with stable disease, achieved an objective response (com-
plete or partial response) to imatinib. Of the two cats without
detectable KIT mutations, one responded. In a phase I clinical trial
of imatinib in tumour-bearing cats (Lachowicz et al., 2005), one case
of MCT with an unknown KIT mutation status showed no objec-
tive tumour response after imatinib at a dose of 15 mg/kg daily.
Based on these previous reports, imatinib can be viewed as ef-
ﬁcacious in certain canine and feline MCTs, and clinical responses
are likely to be associated with KIT mutations. However, aberrant
kinase phosphorylation in canine and felineMCTs could not be solely
attributable to a mutant KIT. In dogs, ﬁve cases that responded to
imatinib had no mutation within the entire nucleotide sequence of
KIT (Isotani et al., 2008). Likewise, no KIT mutation was identiﬁed
in one cat withMCT that responded to imatinib therapy, even though
the entire nucleotide sequence of KIT was examined (Isotani et al.,
2010). Therefore, other mechanisms may underlie the anti-tumour
effect of imatinib in these cases. It is possible that imatinib may
inhibit other aberrantly regulated tyrosine kinases; for example, mu-
tations in PDGFRA and PDGFRBwere found in humans with imatinib-
sensitive mastocytosis (Pardanani et al., 2003; Lahortiga et al., 2008).
Thus, activating mutations in other tyrosine kinases could be driving
the response to imatinib in these KIT mutation negative cases. Al-
ternatively, the samples that were used for nucleotide sequencing
analysis of KIT may not have been of suﬃcient quality for muta-
tion analysis (e.g. the purity of the tumour cells). This is possible,
since some analyses used ﬁne needle aspiration samples that could
potentially be contaminated with a large number of non-neoplastic
cells (e.g. blood cells, inﬂammatory cells and mesenchymal cells).
Most studies have used dosage levels of 10mg/kg daily or higher;
however, Marconato et al. (2008) successfully treated three dogs with
MCTs with a lower dose of imatinib (4.4 mg/kg daily). Their ﬁnd-
ings indicate the possibility that a lower dosage of imatinib could
be suitable for the treatment of canine and feline MCTs. If so, treat-
ment costs and the incidence of side effects would be greatly reduced.
In summary, although imatinib has been shown to have anti-
tumour activity towards canine and felineMCTs, the reported studies
only include a small number of animals. Therefore, large-scale clin-
ical studies are needed to clarify the clinical utility of imatinib for
these tumours.
Other neoplasms and non-neoplastic disorders
In dogs, imatinib (10 mg/kg daily) has also been used to treat a
dog with an unresectable GIST with a KIT exon 11 mutation and a
tumour response was noted (Kobayashi et al., 2013). Currently there
is no known effective chemotherapeutic drug for canine GISTs.
Further studies interrogating the therapeutic effects of imatinib in
canine GISTs are needed to clarify whether this canine tumour type
is a good candidate for imatinib therapy, similar to humans.
A case of feline HES was treated with imatinib at a daily dose
of 9.6 mg/kg (Backlund et al., 2011). This cat showed clinical im-
provement, with normalisation of peripheral eosinophil counts after
imatinib therapy. It is possible that this feline tumour might have
expressed an aberrant kinase, such as the FIP1L1-PDGFRA fusion
kinase, similar to human HES; however, this was not investigated
in that study.
In a phase I clinical trial of imatinib in cats (Lachowicz et al.,
2005), all four cats with vaccine-associated ﬁbrosarcoma (VAFS)
showed tumour stabilisation (<50% change in tumour volume) for
an average of 2 months. It is not known if feline VAFS cells have a
driver mutation in a kinase that is targeted by imatinib. However,
PDGF/PDGFR signalling has been shown to play an important role
in the growth of feline VAFS and imatinib can inhibit the PDGF-
stimulated growth of VAFS cells in vitro and in vivo (Katayama et al.,
2004). It is therefore possible that imatinib may have suppressed
tumour growth by interfering with PDGFR signalling.
1 Response to imatinib was expressed according to the Response Evaluation Cri-
teria in Solid Tumours (RECIST) guidelines in dogs (Nguyen et al., 2013) or humans
(http://www.recist.com/; accessed 26 November 2014).
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Interestingly, in addition to its use in oncology, imatinib
(3 mg/kg daily) has also been examined for treatment of pulmo-
nary arterial hypertension (PAH) in dogs (six cases) (Arita et al., 2013).
Imatinib was clinically effective for PAH caused by mitral regurgi-
tation or chronic ﬁlariasis in all six dogs, presumably by targeting
PDGFR, which is a factor in the molecular pathogenesis of PAH in
humans (Rabinovitch, 2008). That study suggests the potential ther-
apeutic use of imatinib for diseases other than cancer.
Toxicity
The toxic effects associated with imatinib treatment of dogs and
cats are summarised in Table 4. Isotani et al. (2008) treated 21 dogs
with MCTs with imatinib (10 mg/kg) and no clinical or
haematological toxicity, except for one dog that experienced mild
vomiting, was noted. Furthermore no notable toxicity that could be
related to imatinib (10–12.7 mg/kg) was reported in three other
studies that included a total of four dogs with MCTs (Yamada et al.,
2011; Kobayashi et al., 2012; Nakano et al., 2014). Of the 32 dogs
with MCTs that we treated with imatinib (10–12 mg/kg), neutro-
penia, vomiting or elevation of serum liver enzymes, blood urea
nitrogen (BUN) and serum creatinine were observed in a small
number of cases (unpublished data). All of these toxicities im-
proved following reduction or transient withdrawal of imatinib. An
increase in serum alanine aminotransferase (ALT) was also ob-
served in a canine case of GIST treated with imatinib (10 mg/kg),
but serum ALT decreased to normal levels when the dose of imatinib
was reduced (Kobayashi et al., 2013).
Both Marconato et al. (2008) and Arita et al. (2013) used a range
of low doses of imatinib (3–4.4 mg/kg) for the treatment of MCT
or PAH; no haematological or non-haematological adverse effects
were observed. In an experimental setting, progressive liver
toxicity was observed in normal dogs treated with a high dose
of imatinib (100 mg/kg), but not in dogs treated with a dose of
3 mg/kg (Druker and Lydon, 2000).
In a phase I clinical trial, imatinib (1–15 mg/kg) was adminis-
tered to 11 tumour-bearing cats, including cats with VAFS, MCT or
squamous cell carcinoma, and no unacceptable toxicity was noted
(two cats showed mild lethargy or mild vomiting) (Lachowicz et al.
(2005). In the studies of Isotani et al. (2006, 2010), a total of 11 cats
with MCTs were treated with imatinib (10 mg/kg) and no notable
toxicity was observed. In contrast, one cat with HES treated with
imatinib (9.6 mg/kg) developed proteinuric nephropathy (Backlund
et al., 2011). We have also observed proteinuria in a cat with MCT
treated with imatinib (10–12 mg/kg) (unpublished data). This cat
also showed mild vomiting with mild to moderate increase of ALT,
BUN and creatinine.
Based on these ﬁndings, imatinib at an approximate dose of
10 mg/kg or less appears to be well tolerated in dogs and cats, with
some possibility of bone marrow, hepatic, renal and gastrointesti-
nal toxicity in dogs, and hepatic, renal and gastrointestinal toxicity
in cats.
Towards individualised treatment
Since imatinib is considered to have therapeutic activity towards
a certain subset of canine and feline tumours with dysregulated KIT,
it would be beneﬁcial to individualise imatinib treatment accord-
ing to the mutational status of KIT.
The characteristics of the reported canine and feline KIT muta-
tions, and the effects of imatinib in vitro and in clinical cases, are
summarised in Table 5. Fifteen out of 36 reported KITmutations have
been demonstrated to cause constitutive activation of KIT in vitro,
suggesting that they are activating mutations. The most frequent
Table 4
Toxicities associated with imatinib treatment of dogs and cats.
Number of cases Disease Dose (mg/kg)a Treatment period (week) Toxicities (grade)b n Reference
Dogs 21 MCT 10 1–9 Vomiting (1) 1 Isotani et al. (2008)
3 MCT 4.4 11–21 None Marconato et al. (2008)
2 MCT 10–12.7 13 and 45 None Nakano et al. (2014)
1 MCT 10 10 None Yamada et al. (2011)
1 MCT 10 6 None Kobayashi et al. (2012)
32 MCT 10–12 1–43 Vomiting (1) 1 Our laboratory, unpublished data
Neutropenia (1) 2
Increase in ALT (3) 1g
Increase in AST (3) 1g
Increase in ALP (2) 1g
Increase in BUN (1) 1g
Increase in Cr (2) 1g
1 GIST 7c–10 >120d Increase in ALT (2) 1 Kobayashi et al. (2013)
6 PAH 3 4 None Arita et al. (2013)
Cats 11 Variouse 1–15 2–8 Lethargy (1) 1 Lachowicz et al. (2005)
Vomiting (1) 1
10 MCT 10 2–32 None Isotani et al. (2010)
1 MCT 10 33f None Isotani et al. (2006)
1 HES 9.6 8 Proteinuria 1 Backlund et al. (2011)
1 MCT 10–12 26 Vomiting (1) 1h Our laboratory, unpublished data
Proteinuria 1h
Increase in ALT (3) 1h
Increase in BUN (1) 1h
Increase in Cr (1) 1h
MCT, mast cell tumour; GIST, gastrointestinal stromal tumour; PAH, pulmonary arterial hypertension; HES, hyperoeosinophilic syndrome; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; ALP, alkaline phosphatase; BUN, blood urea nitrogen; Cr, creatinine.
a Imatinib was given daily except for the reported case of Kobayashi et al. (2013).
b Grade of toxicities were expressed according to Veterinary Cooperative Oncology Group (2011).
c Imatinib was given every other day.
d The reported period was 20 weeks but the treatment was continued for >120 weeks.
e Includes vaccine-associated ﬁbrosarcoma (n = 4), squamous cell carcinoma (n = 4) and mast cell tumour (n = 1).
f The reported period was 5 weeks but treatment was continued until 33 weeks.
g Toxic events were observed in the same dog.
h Toxic events were observed in the same cat.
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type of canine KIT mutation, the exon 11 ITD mutation, shows vari-
ation in location and in duplicated size, but these ITD mutations
commonly alter the gene sequence around codons 570–590 and have
been shown to cause constitutive activation of KIT. Therefore, despite
the observed variation, the exon 11 ITD mutations are likely to act
as activating mutations.
Eight types of mutant KIT due to an activating mutation, (dogs:
p.Glu417_Thr420dup{Glu417Gln}, p.Asn508Ile and ITD around
codon 570–590; cats: p.Glu415_Thr418dup{Glu415Gln},
p.His419_Leu422delinsLeuIle, p.His419_Ser421delinsLeu, p.Ser477Ile,
and p.Asn506Ile) have been demonstrated to be sensitive to imatinib
in vitro. Moreover, tumours with these imatinib-sensitive muta-
tions, except for two types of exon 8 mutations in cats, showed
objective responses to imatinib in the clinic. Therefore, these acti-
vating mutations are likely to be imatinib-sensitive driver mutations
and may be useful biomarkers for individualisation of imatinib
therapy.
The activation status and susceptibility to imatinib in vitro
of canine KIT with the mutations p.Gln555_Lys557del,
p.Trp556_Val558delinsPhe and p.Val559Asp have not been exam-
ined; however, tumours with these mutations clearly responded to
imatinib in the clinic. Although further molecular analyses are
needed, these mutations may also be useful for individualisation
of imatinib therapy.
Although seven types of KIT mutations (p.Ser479Ile,
p.Gln555_Lys557delinsVal, p.Trp556Arg, p.Trp556_Lys557del,
p.Val558del, p.Leu575Pro and p.Gly826_Ala828delinsAspThr) in
dogs have been shown to be activating mutations, it is not known
if the resulting mutant KITs are sensitive to imatinib in vitro and
in the clinic. A KIT with an activating mutation is not always
sensitive to imatinib. Sensitivity of a KIT mutant to imatinib is
variable and depends on the location of the mutation and/or the
property of the amino acid mutated. For example, in human mas-
tocytosis, the vast majority of adult patients possess an activating
KIT mutation in exon 17 that results in the mutation Asp816Val in
the activation loop of KIT (Garcia-Montero et al., 2006). However,
tumours carrying this mutation have been shown to be resistant
to imatinib (Pardanani, 2013). Likewise, although imatinib has
activity against human GISTs with a mutation in KIT exon 9, this
activity is inferior when compared with GISTs with mutations in
other KIT exons (e.g., exon 11) (Heinrich et al., 2008). Therefore,
molecular and clinical analyses regarding the response of differ-
ently mutated KITs to imatinib are needed to clarify their value as
targets of imatinib.
Table 5
Characteristics of reported canine and feline KIT mutations and effects of imatinib in vitro and in clinical cases.
KIT mutation Tumour Frequency (%) Activation status In vitro effects of imatinib Clinical response to imatinib (n)
Dogs Exons 6–7 p.Asp312_Thr414delinsAla MCT 2.1a NA NA NA
Exon 8 p.Glu417_Thr420dup{Glu417Gln} MCT 4.2b, 6.4a Activatedb,c Suppressionc PR (1)c
p.Gln430Arg MCT 0.5b NA NA NA
Exon 9 p.Ser479Ile MCT 2.6b Activatedb NA NA
p.Asn508Ile MCT 1.6b Activatedb,d Suppressiond PR (1)d
Exon 11 p.Gln555_Lys557del MCT NA NA NA CR (1)e
p.Gln555_Lys557delinsVal MCT 0.5b Activatedb NA NA
p.Trp556Arg MCT NA Activatedf NA NA
p.Trp556_Lys557del MCT 0.5b Activatedf NA NA
GIST 11.2g NA
p.Trp556_Lys557delinsGln GIST 25.0h NA NA NA
p.Trp556_Val558delinsPhe GIST 23.5g NA NA PR (1)i
p.Lys557delInsAsnProv MCT 2.1b NA NA NA
p.Lys557_Val559delinsArg MCT 0.5b NA NA NA
p.Val558del MCT 2.1a Activatedf NA NA
p.Val559Asp MCT NA NA NA CR (1)e
p.Leu575Pro MCT 2.1a Activatedf,j NA NA
GIST 25.0h NA
MEL 2.0k NA
AML 4.8l NA
Various ITD around codon 570–590 MCT 9.1–17.0a,b,m,n Activatedb,f,j,o,p Suppressionp CR/PR (16)q,r
Exon 15 p.Ser714del MCT 2.1a NA NA NA
Exon 17 p.Asp815Asn AML 4.8l NA NA NA
p.Asp815Val AML 9.5l NA NA NA
p.Lys817Arg AML 4.8l NA NA NA
p.Gly826_Ala828delinsAspThr MCT 0.5b Activatedb NA NA
Cats Exon 6 p.Met319_Thr322delinsIle MCT 5.9p NA NA NA
Exon 8 p.Glu415Lys MCT 4.2s NA NA NA
p.Glu415_Thr418dup{Glu415Gln} MCT 40.3p, 8.3s Activatedp Suppressionp CR/PR (6)p,t
p.His419_Ser421delinsLeu MCT 4.2s NA NA NA
p.His419_Leu422delinsLeuIle MCT 1.6p Activatedp Suppressionp NA
p.His419_Ser421delinsLeu MCT 3.2p Activatedp Suppressionp NA
Exon 9 p.Ser477Ile MCT 19.4p, 41.7 s Activatedp Suppressionp PR (2)p
p.Glu491_Asn497del MCT 4.2s NA NA NA
p.Arg493Lys MCT 4.2s NA NA NA
p.Asn506Ile MCT 4.8p Activatedp Suppressionp PR (1)p
Exon 11 p.Tyr554_Glu555delinsCysLysThrGln MCT 1.6p NA NA NA
p.Glu555K MCT 4.2s NA NA NA
p.Trp558_Lys559del GIST NAu NA NA NA
p.Glu563Lys MCT 4.2s NA NA NA
NA, not available; MCT, mast cell tumour; GIST, gastrointestinal stromal tumour; MEL, melanoma; AML, acute myeloid leukaemia; CR, complete response; PR, partial response.
a Takeuchi et al. (2013); b Letard et al. (2008); c Kobayashi et al. (2012); d Yamada et al. (2011); e Nakano et al. (2014); f Ma et al. (1999); g Gregory-Bryson et al. (2010);
h 1/4 dogs had a mutation, Frost et al. (2003); i Kobayashi et al. (2013); j Liao et al. (2002); k Chu et al. (2013); l Usher et al. (2009); m Webster et al. (2006); n Zemke
et al. (2002); o London et al. (1999); p Isotani et al. (2010); q Isotani et al. (2008); r Our laboratory unpublished data; s Sabattini et al. (2013); t Isotani et al. (2006); u Morini
et al. (2011); v Mutations K557 InsF and K557 N InsP in the original report are identical with the mutation p.Lys557delInsAsnPro (conﬁrmed with the author of the original
report).
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Almost half of the KIT mutations identiﬁed in canine and feline
tumours have not yet been characterised with regard to activation
status and imatinib susceptibility. However, detection of speciﬁcmu-
tations in KIT, such as exon 11 ITD mutations in canine MCTs and
exon 8 ITD mutations in feline MCTs, is likely to be valuable for
individualisation of imatinib treatment. Further studies evaluat-
ing the relationship between KITmutation status and the therapeutic
effects of imatinib in canine and feline malignancies are necessary
to enable the individualisation of imatinib therapy.
Conclusions
Imatinib has therapeutic activity towards a certain subset of canine
and felineMCTs. In addition toMCTs, other tumours suchas canineGISTs
could respond to imatinib therapy; further clinical studies are needed
to verify imatinib eﬃcacy towards these tumours. Since the therapeu-
tic activity of imatinib is associatedwith the presence of constitutively
activated KIT, it would be beneﬁcial to individualise imatinib treat-
ment according to the mutation status of KIT. Some KIT mutations,
especially those such as exon 11 ITD mutations in dogs and exon 8
ITD mutations in cats, are promising candidate biomarkers for
individualisation of imatinib therapy for MCTs. Although imatinib
appears to be safe for use in dogs and cats, further accumulation of cases
and long-term follow-up are needed before making conclusions
regarding the safety and toxicity of imatinib.
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